Luye Pharma Group has announced the beginning of the phase I clinical study of the company’s self-developed microsphere injection LY03009 in Australia

China Cell Valley

Nanjing Jiangbei New Area Biopharmaceutical Public Platform

TransThera(Enterprise in the NJBPV) and LG Chem subsidiary life and science company jointly announced that clinical application for TT-01025 was submitted to the FDA on Oct 23rd 2020